Skip to main content

Main menu

  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us

Clinical Medicine Journal

  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

User menu

  • Log in

Search

  • Advanced search
RCP Journals
Home
  • Log in
  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us
Advanced

Clinical Medicine Journal

clinmedicine Logo
  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

Managing breathlessness in advanced disease

Barbara Powell
Download PDF
DOI: https://doi.org/10.7861/clinmedicine.14-3-308
Clin Med June 2014
Barbara Powell
ALOROS Hospice, Leicester, UK
Roles: consultant in palliative medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: barbarapowell@loros.co.uk
  • Article
  • Figures & Data
  • Info & Metrics
Loading
KEYWORDS 
  • Breathlessness
  • multi-professional approach
  • opioids
  • subjective
  • symptom mastery

Breathlessness in advanced malignant and non-malignant disease is frequently chronic and refractory. It persists at rest and on minimal activity despite optimal management of the underlying disease process.

Concept of breathlessness

The terms dyspnoea (‘difficult breathing’), breathlessness and shortness of breath are often used interchangeably. Breathlessness is the term most often used by patients. Other patient descriptors, such as air hunger, increased work of breathing, chest tightness and a feeling of suffocation, have been disappointing in identifying specific pathophysiologies to allow targeted intervention. Temporal patterns of breathlessness, including continuous or episodic breathlessness, with or without apparent triggers, are a current topic of research1 in the hope that such discrimination will inform future management choices.

Breathlessness is a symptom that can only be described and interpreted by the patient.2 It should be considered as distinct from the traditionally observed physiological parameters that physicians use when assessing for respiratory compromise, such as respiratory rate, oxygen saturation and the use of accessory muscles.

[Breathlessness is] a subjective experience of breathing discomfort that consists of qualitatively distinct sensations that vary in intensity. The experience derives from interactions among multiple physiological, psychological, social and environmental factors, and may induce secondary, physiological and behavioural responses.

American Thoracic Society (1999)1

Prevalence and impact

Breathlessness is common in patients with advanced life-threatening illnesses of all types. The prevalence reaches 90% in cancer, 95% in chronic obstructive pulmonary disease (COPD), 88% in cardiac failure, 80% in end-stage renal disease and 85% in advanced neurological disease.3 Both prevalence and intensity increase as death approaches.

Breathlessness causes significant suffering to patients and to carers, profoundly disrupting day-to-day functioning and causing social isolation. It can engender helplessness, be linked to thoughts of impending death and be a major trigger for hospital admission.

Mechanism of refractory breathlessness

Unlike the normal ‘physiological’ feeling of being out of breath generated in health by physical exertion (eg climbing stairs at speed), the experience of breathlessness in advanced disease is more than a simple symptom, rather a complex set of interactions between physical, psychological and emotional factors that are further modulated by an individual's past experiences, expectations and fears for the future.

It is all too easy to underestimate the experience of breathlessness and the associated suffering. The sensation of breathlessness is generated when higher cortical centres perceive what the respiratory system can provide as inadequate or unsustainable to meet the body's requirements, and the patient may perceive a significant threat to survival (Fig 1).

Fig 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig 1.

Mechanism of breathlessness in advanced disease.

Recent functional neuroimaging studies have shown that breathlessness, irrespective of cause or stimulus, activates distinct areas in the limbic system.4 This region is rich in opioid receptors and probably generates the conscious awareness of breathlessness and the associated sensation of unpleasantness.

Assessment

Breathlessness is a subjective symptom that cannot easily be quantified, and there is no commonly agreed assessment tool.5 Few parameters measured in pulmonary function laboratories are representative of real life, and they are too burdensome for use in patients with advanced disease states. The assessment of breathlessness should reflect patients’ reporting of both severity and affective components.

When assessing any response to intervention, consideration must reflect patient-relevant outcomes. Success, therefore, may be a reduction in intensity of breathlessness, a reduction in psychological distress, an increase in activity levels or a reduction in hospital admissions.

In patients with advanced disease, there is little potential of returning to a non-breathless state. There may be a delay in the patient developing confidence in an intervention before achieving mastery of breathlessness and increased performance. Small objective increments (5.5 mm on a 100 mm visual analogue scale) can translate into meaningful improvement for patients.6

Treatment

Ensure that treatment for the underlying disease is optimised in the context of disease trajectory, performance status and patients’ wishes. Patients with advanced cancer can develop heart failure but respond to treatment with significant improvement in symptoms. Conversely, treating a pleural effusion will not benefit a dying patient. Potentially reversible causes of breathlessness include pulmonary embolus, infection, arrhythmia, anaemia and ascites.

Evidence base for non-pharmacological treatment

Two Cochrane reviews and four systematic reviews published since 20087–9 have recommended non-pharmacological approaches for intractable breathlessness associated with advanced disease. These are summarised in Table 1.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table 1.

Non-pharmacological interventions to manage breathlessness.

Evidence base for pharmacological treatments

Opioids

Opioids are the mainstay of pharmacological intervention for breathlessness and multiple randomised controlled trials (RCTs) and systematic reviews11,12 have shown significant reductions in breathlessness with the use of oral or parenteral opioids in patients with advanced disease. Most studies have used morphine, but a class effect is assumed.

Opioids are proposed both to reduce the spontaneous respiratory motor response to hypercapnia and hypoxia and to modulate the central processing such that perceptual sensitivity to breathlessness is diminished.13Important gaps remain in the knowledge base regarding variability in the degree of opioid responsiveness and tolerability between patients. Recent work suggests that younger patients and those who experience the greatest severity of breathlessness are most likely to benefit.

Fears around safety are common but unsubstantiated. Several studies have shown no evidence of significant opioid-induced respiratory depression or hastened death, such that their use is now recommended in advanced respiratory disease.14

Expert opinion regarding the initiation of opioids for breathlessness lies in two camps: commencement of long-acting morphine (10 mg daily)12 vs more gradual titration using low-dose, short-acting morphine.15 Local practice in our hospital favours the second approach, starting with low-dose, short-acting morphine (1–2 mg twice daily plus 1–2 mg as required) and with judicious weekly uptitration to the minimum effective dose that improves tolerability of breathlessness and limits opioid-related adverse effects. Side effects, especially constipation, should be anticipated and managed proactively. Recent studies looking at the longer term benefits and acceptability of low-dose opioids for patients with COPD are encouraging.15 For patients already established on opioids for pain, an increment of 25% above baseline is recommended.

Box 1. Breathlessness in the last days of life.


Embedded Image

Oxygen

Long-term oxygen therapy improves both survival and quality of life for patients with COPD with significant chronic hypoxia. Oxygen is often prescribed for palliation of breathlessness in the setting of other advanced disease, but the evidence base does not support this practice in the absence of hypoxia. A Cochrane review and a large RCT comparing oxygen and room air via nasal cannula showed no additional symptomatic benefit with oxygen over room air in non-hypoxic patients with malignant and non-malignant aetiologies.16–18 Movement of air across the face may be beneficial, and this can readily be achieved using a fan. Opioids have been found to be significantly better than oxygen in reducing breathlessness.13

Short-burst oxygen supplementation may prevent desaturation during exercise but may not relieve breathlessness. Careful assessment of symptomatic benefit on an individual basis is recommended.

Anxiolytics

Significant interplay between breathlessness and anxiety is often present, making it difficult for patients and clinicians to distinguish the primary source of distress.

Benzodiazepines are often used for breathlessness, but the evidence base is sparse. Recent reviews identified only a non-significant trend for cancer- and non-cancer-related breathlessness.19 Two more-recent RCTs support a modest benefit of midazolam, particularly in combination with morphine.20

In practice, a therapeutic trial of low-dose benzodiazepine (lorazepam 0.5–1.0 mg sublingually as required) would be cautiously recommended when anxiety is prominent and breathlessness is not amenable to non-pharmacological interventions and opioids.

Antidepressants with anxiolytic properties, such as mirtazapine and citalopram, may have a role alongside non-pharmacological interventions (Box 1).

Conclusion

Breathlessness is the subjective experience of not being able to breathe comfortably. It is a common and distressing multi-dimensional symptom. An interdisciplinary approach that considers both non-pharmacological and pharmacological measures can substantially reduce its impact for patients (Fig 2).

Fig 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig 2.

Management of breathlessness in advanced disease.

Key points

  • Severity of breathlessness is unrelated to measurable parameters or disease status

  • No single intervention is likely to relieve refractory breathlessness; aim to change perception and experience of breathlessness

  • The most effective regimens for palliation of breathlessness include concurrent use of non-pharmacological and pharmacological interventions

  • Opioids can safely reduce the subjective sensation of intractable breathlessness

  • Oxygen may correct hypoxia, and movement of air palliates breathlessness

  • © 2014 Royal College of Physicians

References

  1. ↵
    1. Parshall MB,
    2. Schwartzstein RM,
    3. Adams L,
    4. et al.
    An official American Thoracic Society statement: update on the mechanisms, assessment and management of dyspnea. Am J Respir Crit Care Med 2012;185:435–52.doi:10.1164/rccm.201111-2042ST
    OpenUrlCrossRefPubMed
  2. ↵
    1. Simon ST,
    2. Higginson I,
    3. Benalia H,
    4. et al.
    Episodic and continuous breathlessness: a new categorization of breathlessness. J Pain Symptom Manage 2013;45:1010–29.
    OpenUrl
  3. ↵
    1. Solano JP,
    2. Gomes B,
    3. Higginson IJ
    . A comparison of symptom prevalence in far advanced cancer, aids, heart disease, chronic obstructive pulmonary disease and renal disease. J Pain Symptom Manage 2006;31:58–69.doi:10.1016/j.jpainsymman.2005.06.007
    OpenUrlCrossRefPubMed
  4. ↵
    1. von Leupoldt A,
    2. Sommer T,
    3. Kegat S,
    4. et al.
    Dyspnoea and pain share emotion-related brain network. Neuroimage 2009;48:200–6.doi:10.1016/j.neuroimage.2009.06.015
    OpenUrlCrossRefPubMed
  5. ↵
    1. Dorman S,
    2. Byrne A,
    3. Edwards A
    . Which measurement scales should we use to measure breathlessness in palliative care? A systematic review. Palliat Med 2007;21:177–91.doi:10.1177/0269216307076398
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Johnson MJ,
    2. Bland JM,
    3. Oxberry SG,
    4. et al.
    Clinically important differences in the intensity of chronic refractory breathlessness. J Pain Symptom Manage 2013;46:957–63.doi:10.1016/j.jpainsymman.2013.01.011
    OpenUrlCrossRef
  7. ↵
    1. Bausewein C,
    2. Booth S,
    3. Gysels M,
    4. Higginson I
    . Non-pharmacological interventions for use in breathlessness in the advanced stages of malignant and non-malignant diseases. Cochrane Database Syst Rev 2008;CD005623.
  8. ↵
    1. Yates P,
    2. Zhao I
    . Update on complex nonpharmacological interventions for breathlessness. Curr Opin Support Palliat Care 2012;6:144–52.doi:10.1097/SPC.0b013e3283536413
    OpenUrlCrossRefPubMed
  9. ↵
    1. Booth S,
    2. Moffat C,
    3. Burkin J,
    4. et al.
    Nonpharmacological interventions for breathlessness. Curr Opin Support Pallat Care 2011;5:77–86.doi:10.1097/SPC.0b013e3283460c93
    OpenUrlCrossRefPubMed
    1. Farquhar M,
    2. Prevost T,
    3. Bentley A
    et al. Impact of a breathlessness intervention service on patients with advanced cancer: preliminary results of a randomised controlled trial, poster showing -preliminary results. Poster presented at the 8th NCRI Cancer Conference, 4–7 November 2012, Liverpool, UK (Poster A198).
  10. ↵
    1. Jennings AL,
    2. Davies AN,
    3. Higgins JP,
    4. et al.
    A systematic review of the use of opioids in the management of dyspnoea. Thorax 2002;57:939–44.doi:10.1136/thorax.57.11.939
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Abernethy AP,
    2. Currow DC,
    3. Frith P,
    4. et al.
    Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ 2003;327:523–28.doi:10.1136/bmj.327.7414.523
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Mahler DA
    . Opioids for refractory dyspnea. Expert Rev Respir Med 2013;7:123–35.doi:10.1586/ers.13.5
    OpenUrlCrossRefPubMed
  13. ↵
    1. Hallenbeck J
    . Pathophysiologies of dyspnea explained: why might opioids relieve dyspnea and not hasten death? Special report. J Palliat Med 2012;15:1–6.doi:10.1089/jpm.2011.0167
    OpenUrlCrossRef
  14. ↵
    1. Rocker GM,
    2. Simpson CA,
    3. Young J,
    4. et al.
    Opioid therapy for refractory dyspnea in patients with advanced chronic obstructive pulmonary disease: patients’ experiences and outcomes. CMAJ 2012;184:E497–504.doi:10.1503/cmaj.111758
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Uronis HE,
    2. McCory DC,
    3. Samsa GP,
    4. et al.
    Symptomatic oxygen for non-hypoxaemic chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2011;6:CD006429.
    OpenUrlPubMed
  16. ↵
    1. Uronis HE,
    2. Currow DC,
    3. McCory DC,
    4. et al.
    Oxygen for relief of dyspnoea in mildly or non-hypoxic patients with cancer: a systematic review and meta-analysis. Br J Cancer 2008;98:294–9.doi:10.1038/sj.bjc.6604161
    OpenUrlCrossRefPubMed
  17. ↵
    1. Abernathy AP,
    2. McDonald CF,
    3. Frith PA,
    4. et al.
    Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trial. Lancet 2010;376:784–93.doi:10.1016/S0140-6736(10)61115-4
    OpenUrlCrossRefPubMed
  18. ↵
    1. Simon ST,
    2. Higginson IJ,
    3. Booth S,
    4. et al.
    Benzodiazepines for the relief of breathlessness in advanced malignant and non–malignant diseases in adults. Cochrane Database Syst Rev 2010;(1):CD007354.
  19. ↵
    1. Currow DC,
    2. Abernethy AP
    . Potential opioid-sparing effect of -regular benzodiazepines in dyspnea: longer duration of studies needed. J Pain Symptom Manage 2010;40:e1–2.doi:10.1016/j.jpainsymman.2010.07.002
    OpenUrlCrossRefPubMed
Back to top
Previous articleNext article

Article Tools

Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Managing breathlessness in advanced disease
Barbara Powell
Clinical Medicine Jun 2014, 14 (3) 308-311; DOI: 10.7861/clinmedicine.14-3-308

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Managing breathlessness in advanced disease
Barbara Powell
Clinical Medicine Jun 2014, 14 (3) 308-311; DOI: 10.7861/clinmedicine.14-3-308
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Concept of breathlessness
    • Prevalence and impact
    • Mechanism of refractory breathlessness
    • Assessment
    • Treatment
    • Conclusion
    • References
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Discussing and planning care for people approaching the end of their life
  • Palliative care for frail older people
  • Managing pain in advanced illness
Show more CME SECTION: Palliative medicine

Similar Articles

FAQs

  • Difficulty logging in.

There is currently no login required to access the journals. Please go to the home page and simply click on the edition that you wish to read. If you are still unable to access the content you require, please let us know through the 'Contact us' page.

  • Can't find the CME questionnaire.

The read-only self-assessment questionnaire (SAQ) can be found after the CME section in each edition of Clinical Medicine. RCP members and fellows (using their login details for the main RCP website) are able to access the full SAQ with answers and are awarded 2 CPD points upon successful (8/10) completion from:  https://cme.rcplondon.ac.uk

Navigate this Journal

  • Journal Home
  • Current Issue
  • Ahead of Print
  • Archive

Related Links

  • ClinMed - Home
  • FHJ - Home
clinmedicine Footer Logo
  • Home
  • Journals
  • Contact us
  • Advertise
HighWire Press, Inc.

Follow Us:

  • Follow HighWire Origins on Twitter
  • Visit HighWire Origins on Facebook

Copyright © 2021 by the Royal College of Physicians